Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long Term Extension Study in Patients With Primary Hyperoxaluria | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hyperoxaluria, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, kidney disorder, metabolic disease, primary hyperoxaluria, primary hyperoxaluria type 1, primary hyperoxaluria type 2, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT04042402 | |
| Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, primary hyperoxaluria type 1, urinary system disorder | Recruiting | Phase 2 | 2025-12-24 | NCT04580420 | |
| Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | Solid Tumors, Adult | Recruiting | Phase 1 | 2025-11-06 | NCT06504368 |